Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
For a brief moment, there was significant investor anxiety that the ‘holy mother’ of all drug launches might burst like a balloon. A report that the new Tecfidera multiple sclerosis pill was possibly linked to a patient death sent shares downward amid speculation about whether the Biogen Idec drug may have a side effect problem that could thwart blockbuster sales estimates. But by the time the markets closed, the drugmaker had worked feverishly to dispel such concerns.
Help employers find you! Check out all the jobs and post your resume.
For a brief moment, there was significant investor anxiety that the ‘holy mother’ of all drug launches might burst like a balloon. A report that the new Tecfidera multiple sclerosis pill was possibly linked to a patient death sent shares downward amid speculation about whether the Biogen Idec drug may have a side effect problem that could thwart blockbuster sales estimates. But by the time the markets closed, the drugmaker had worked feverishly to dispel such concerns.
Help employers find you! Check out all the jobs and post your resume.
